S&P falls for fourth day as Mueller subpoena weighs

Bullish Options Activity in Alibaba (BABA) Targets Upside in Shares -Susquehanna

Susquehanna options strategist Alison Edwards notes bullish options activity in Alibaba (NYSE: BABA), investors purchased ~7,500 May 210 Calls for $7.30 and 2,500 Jul 210/250 call spreads for up to $9.00.

Dollar General (DG) PT Raised to $97 at Loop Capital

Loop Capital raised its price target on Dollar General (NYSE: DG) to $97.00 (from $87.00) while maintaining a Hold rating.

Analyst Anthony Chukumba notes the company posted solid F4Q 2017 results and they believe the company's much better-than-expected F2018 earnings guidance "is largely a function of the fact... More

RBC Sees 10-15% Move in Alexion Pharma (ALXN) Following ALXN-1210 Results

RBC Capital analsyt Kennen MacKay was positive on Alexion Pharma (NASDAQ: ALXN) after ALXN-1210 hit its hurdle in the 1st of 2 Phase 3 trials.

MacKay called the results a "win, but note a full re-rate scenario." He sees a 10-15% move.

Dollar General (DG) PT Raised to $125 at Deutsche Bank on 4Q Print; 'Clearing All Major Hurdles'

Deutsche Bank raised its price target on Dollar General (NYSE: DG) to $125.00 (from $121.00) while maintaining a Buy rating, following the company's fourth quarter earnings report.

Analyst Paul Trussell comments, "Post DLTRs shortfall, investors were nervous leading into DGs print on... More

JPMorgan Reiterates Overweight on Alexion Pharma (ALXN) Following Phase 3 Results

JPMorgan reiterated an Overweight rating and $176.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following the company's positive top-line results from the PNH naïve phase 3 study of ALXN1210 versus Soliris.

Analyst Anupam Rama believes that the data is "a clear win for ALXN1210 in... More

Alexion (ALXN) to See Releif Rally on ALXN-1210 Results - BMO

BMO Capital analyst M. Ian Somaiya expects shares of Alexion Pharmaceuticals (NASDAQ: ALXN) trade higher as investors breathe a sigh of relief following release of Phase 3 ALXN-1210 data.

"The treatment naïve study met most investor expectations, meeting the non-inferiority primary endpoint (some... More